Targinta's board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén's resignation as CEO. Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development companies. Previous experiences include various positions such as CEO, business area manager and COO.

Peter has good knowledge in product development, sales, marketing, capitalization, preclinical development and GMP manufacturing. For the past two years, Peter has worked as COO in Xintela.